New biomarker for pancreatic cancer says potential therapy responsible small survival rate

According to new research conducted at the University of Cincinnati the researchers have come across a biomarker that is known as phosphatidylserine for the pancreatic cancer. It is proved that the potential therapy for this condition could lead to small survival rate.
 Through this research the team has investigated the effectiveness and systemic biodistribution of SapC-DOPS nanovesicles in the animal models. They found out that targeting certain cancer cells that did not showed any toxic effects in non-tumor tissues. Through this they can target cell membrane of pancreatic and could destroy it without any harm to normal tissues.
 The lead research of the study, Xiaoyang Qi, PhD, associate professor of hematology oncology at UC explains, “Pancreatic cancer is usually asymptomatic in the early stages, while frequently invading lymph nodes and the liver, and less often the lungs and visceral organs. Current treatments, including surgery, chemotherapy and radiation therapy, have failed to improve long-term survival.”